We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bispecific Antibody Boosts Sensitivity of Brain Cancer PET Scans

By LabMedica International staff writers
Posted on 03 Nov 2015
A bispecific antibody was developed that is taken up by glioblastoma cells in a manner that increases the specificity and intensity of signals detected by PET (positron emission tomography) scanning.

Investigators at the University of Wisconsin (Madison, USA) used a click chemistry approach to synthesize an antibody that recognized both epidermal growth factor receptor (EGFR) and CD105. More...
Click chemistry generates substances quickly and reliably by joining small units together. It is not a single specific reaction, but is descriptive of a method for generating products that follows examples in nature, which also generates substances by joining small modular units.

CD105 (also known as endoglin) has a crucial role in angiogenesis, therefore, making it an important protein for tumor growth, survival, and metastasis of cancer cells to other locations in the body. EGFR is the cell-surface receptor for members of the epidermal growth factor family of extracellular protein ligands. Mutations affecting EGFR expression or activity could result in cancer.

The investigators created a bispecific antibody from CD105 and EFGR specific Fab fragments that also contained a radioactive label detectable by PET. The compound was injected into mice that had received human glioblastoma transplants, and after 36 hours the animals were examined by PET scanning.

Results published in the September 28, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed a significantly enhanced tumor uptake and tumor-to-background ratio (compared with each monospecific Fab tracer. The combination of highly specific tumor uptake of the signal with extremely low background noise enabled visualization of small tumor nodules (less than five millimeters in diameter).

Senior author Dr. Weibo Cai, associate professor of radiology and medical physics at the University of Wisconsin, said, "As we learn more about cancer and what distinguishes it from healthy tissue we are able to bring to bear our expanding ability to detect and manipulate genes, proteins, and other molecules, both for detection and for therapy."

Related Links:

University of Wisconsin



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.